Llwytho...
Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease
OBJECTIVE: To investigate the effects of monoclonal antibodies against Aβ on cognition, function, amyloid PET and other biomarkers, as well as risk for amyloid-related imaging abnormalities (ARIA) and other adverse events, in Alzheimer’s disease (AD). METHODS: Pubmed, Web of Science, ClinicalTrials....
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Ageing Res Rev |
|---|---|
| Prif Awduron: | , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8161699/ https://ncbi.nlm.nih.gov/pubmed/33831607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.arr.2021.101339 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|